National Science Library, Chinese Academy of Sciences
  登录 机构网站 ENGLISH
您当前的位置是:首页->详细浏览

期刊名称: CLINICAL INFECTIOUS DISEASES
Volume:56    Issue:12        Page:1685-1694
ISSN:1058-4838

10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America期刊论文

作者: Boucher HW Talbot GH Benjamin DK Bradley J Guidos RJ
DOI:10.1093/cid/cit152

服务链接:
页码: 1685-1694
被引频次: 438
出版者: OXFORD UNIV PRESS INC
期刊名称: CLINICAL INFECTIOUS DISEASES
ISSN: 1058-4838
卷期: Volume:56    Issue:12
语言: English
摘要: Infections caused by antibiotic-resistant bacteria, especially the "ESKAPE" pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually approved for marketing in the United States continues to decline. We identified 7 drugs in clinical development for treatment of infections caused by resistant GNB. None of these agents was included in our 2009 list of antibacterial compounds in phase 2 or later development, but unfortunately none addresses the entire spectrum of clinically relevant GNB resistance. Our survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive. IDSA stresses our conviction that the antibiotic pipeline problem can be solved by the collaboration of global leaders to develop creative incentives that will stimulate new antibacterial research and development. Our aim is the creation of a sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 as called for in IDSA's "10 x '20 Initiative."
相关主题: INFECTIOUS DISEASES, NXL104, drug development, MICROBIOLOGY, antimicrobials, ACQUIRED BACTERIAL PNEUMONIA, IMMUNOLOGY, SIDEROPHORE MONOSULFACTAM BAL30072, CEFTAZIDIME, gram-negative bacilli, antibacterial agents, PSEUDOMONAS-AERUGINOSA, CLINICAL-TRIALS, RESISTANCE, clinical trials, BETA-LACTAMASES, antibiotic pipeline, IN-VITRO ACTIVITY, Gram-Negative Bacterial Infections - microbiology, Gram-Negative Bacteria - drug effects, United States, Drug Industry, Humans, Drug Resistance, Bacterial, Biomedical Research, Gram-Negative Bacterial Infections - drug therapy, Societies, Anti-Bacterial Agents - administration & dosage, Clinical Trials, Phase II as Topic, Drug Discovery - statistics & numerical data,

相关文献推荐:

问图书管理员更多图书管理员

学科咨询馆员
学科馆员

电话:
邮件:
问图书馆员

图标说明

在线获取原文 原文传递 详细信息 图书在架状态 图书馆际互借 问图书馆员

常见问题

图书馆开放时间 图书馆位置 借阅要求 您在使用中发现的任何错误,都可以向我们 【报告错误】,非常感谢!

作者信息:×